Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

3.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

653
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
653
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Overlapping Case of IgG4-related Disease and Klinefelter Syndrome with Lupus-like Serological and Neurological Features: A Case Report and Literature Review.

Internal medicine (Tokyo, Japan)·2020
Same author

Elevated expression of BAFF receptor, BR3, on monocytes correlates with B cell activation and clinical features of patients with primary Sjögren's syndrome.

Arthritis research & therapy·2020
Same author

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.

Arthritis research & therapy·2020
Same author

Identification of novel genes associated with dysregulation of B cells in patients with primary Sjögren's syndrome.

Arthritis research & therapy·2020
Same author

Longitudinal immune cell monitoring identified CD14<sup>++</sup> CD16<sup>+</sup> intermediate monocyte as a marker of relapse in patients with ANCA-associated vasculitis.

Arthritis research & therapy·2020
Same author

Effectiveness of tocilizumab in Behcet's disease: A systematic literature review.

Seminars in arthritis and rheumatism·2020

Related Experiment Video

Updated: Mar 19, 2026

Using an Automated Cell Counter to Simplify Gene Expression Studies: siRNA Knockdown of IL-4 Dependent Gene Expression in Namalwa Cells
10:34

Using an Automated Cell Counter to Simplify Gene Expression Studies: siRNA Knockdown of IL-4 Dependent Gene Expression in Namalwa Cells

Published on: April 14, 2010

16.1K

[IL-6 blockade].

Yuko Kaneko, Tsutomu Takeuchi

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |June 18, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Tocilizumab effectively treats rheumatoid arthritis by blocking interleukin-6 (IL-6) signaling. Combination therapy with methotrexate enhances remission rates, but careful monitoring for adverse events like hepatotoxicity and infection is crucial.

    More Related Videos

    A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model
    08:38

    A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model

    Published on: March 3, 2023

    1.8K
    Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
    08:43

    Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

    Published on: January 31, 2020

    7.4K

    Related Experiment Videos

    Last Updated: Mar 19, 2026

    Using an Automated Cell Counter to Simplify Gene Expression Studies: siRNA Knockdown of IL-4 Dependent Gene Expression in Namalwa Cells
    10:34

    Using an Automated Cell Counter to Simplify Gene Expression Studies: siRNA Knockdown of IL-4 Dependent Gene Expression in Namalwa Cells

    Published on: April 14, 2010

    16.1K
    A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model
    08:38

    A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model

    Published on: March 3, 2023

    1.8K
    Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
    08:43

    Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

    Published on: January 31, 2020

    7.4K

    Area of Science:

    • Immunology
    • Rheumatology
    • Pharmacology

    Background:

    • Interleukin-6 (IL-6) is a key cytokine in rheumatoid arthritis (RA) pathogenesis.
    • Tocilizumab targets the IL-6 receptor, inhibiting IL-6 signaling pathways.

    Purpose of the Study:

    • To evaluate the clinical and radiographic efficacy of tocilizumab in rheumatoid arthritis.
    • To compare tocilizumab monotherapy with methotrexate and combination therapy.

    Main Methods:

    • Review of clinical studies on tocilizumab efficacy.
    • Assessment of tocilizumab monotherapy versus methotrexate.
    • Evaluation of tocilizumab in combination with methotrexate.

    Main Results:

    • Tocilizumab monotherapy demonstrates superior efficacy compared to methotrexate.
    • Combination therapy with methotrexate is more effective than tocilizumab monotherapy for inducing remission.
    • Clinical and radiographic benefits of tocilizumab are established.

    Conclusions:

    • Tocilizumab is an effective treatment for rheumatoid arthritis.
    • Combination therapy offers enhanced remission induction.
    • Potential adverse events include hepatotoxicity and infection, requiring vigilance.